Albireo Increases 2021 Bylvay™ (odevixibat) Sales Guidance
January 05, 2022 09:00 ET
|
Albireo Pharma, Inc.
– Bylvay net sales guidance revised to $6-7M vs. expectations of $3-4M – Unaudited cash of at least $248M, updates guidance with cash into 2024 – BOLD Phase 3 study in biliary atresia is over 50%...
Albireo Announces Positive Topline Data from Phase 1 Study of A3907
December 16, 2021 08:30 ET
|
Albireo Pharma, Inc.
– First oral, systemic ASBT inhibitor was safe and well tolerated – Secondary and exploratory objectives show favorable pharmacokinetics and systemic exposure, while providing target engagement...
Albireo Presenting New Bylvay™ (odevixibat) Data at NASPGHAN 2021
December 13, 2021 08:30 ET
|
Albireo Pharma, Inc.
– Data show significant correlations in serum bile acid reductions and long-term improvements in pruritus and sleep – Reductions in serum bile acids and improvements in pruritus with and without...
Albireo Announces Changes to R&D Organization
December 09, 2021 09:00 ET
|
Albireo Pharma, Inc.
BOSTON, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced the upcoming departure of Pat Horn,...
Albireo Expands Leadership with Constantine Chinoporos as Chief Business Officer
December 02, 2021 08:30 ET
|
Albireo Pharma, Inc.
BOSTON, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced the appointment of Constantine...
Albireo Announces New Phase 3 Data for Bylvay™ (odevixibat) in PFIC and First Reveal of New Next Generation Bile Acid Modulator Data at AASLD The Liver Meeting® 2021
November 12, 2021 08:00 ET
|
Albireo Pharma, Inc.
– Evidence of long-term clinical treatment benefit of Bylvay™ (odevixibat) showing improved liver health and function across PFIC types – – Data show Bylvay therapy up to 128 weeks, sustained...
Albireo to Present at Upcoming Investor Conferences
November 10, 2021 08:30 ET
|
Albireo Pharma, Inc.
BOSTON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and...
Albireo Reports Q3 Financial Results and Business Update
November 04, 2021 08:30 ET
|
Albireo Pharma, Inc.
– Bylvay™ (odevixibat) approved in the U.S. and Europe, partial Q3 ’21 revenue of $1.1 million– – ASSERT & BOLD Phase 3 studies enrolling, on track for topline data readouts – – 12 abstracts...
Albireo to Report Third Quarter 2021 Financial Results on November 4
October 28, 2021 08:30 ET
|
Albireo Pharma, Inc.
BOSTON, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that management will host a...
Albireo to Showcase New Data at AASLD The Liver Meeting® 2021
October 15, 2021 08:30 ET
|
Albireo Pharma, Inc.
– Seven abstracts accepted highlighting data in pediatric cholestatic and viral liver diseases – – Phase 3 Bylvay™ (odevixibat) data presentations on long-term treatment benefits show evidence of...